Virtual Library
Start Your Search
S.F. Yuan
Author of
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-071 - High Id1 Expression in Lung Cancer: A Favorable Predictor after Adjuvant Chemotherapy (ID 36)
09:30 - 09:30 | Author(s): S.F. Yuan
- Abstract
Background:
Overexpression of Id family proteins inhibits cell differentiation and enhances cell proliferation and invasiveness. An elevated Id1 expression was observed in lung cancer cell lines as well as lung cancer tissues. Nude mice study further confirmed an increased tumor growth in Id1-overexpressing cells and a decreased tumor growth in Id1-knockdowned cells. Id1 protein may provide a pivot role in non-small cell lung cancer (NSCLC) development.
Methods:
Effects of Id1 expression on cytotoxicity of paclitaxel and cisplatin, and the mechanisms underlying these effects, were analyzed in A549, H460 and H520 cells in vitro. The influence of Id1 expression on xenograft lung tumor growth was investigated in nude mice, following treatment with paclitaxel and cisplatin. Eighty-three surgically-treated NSCLC patients receiving adjuvant paclitaxel and cisplatin were included for clinical analysis. Id1 expression in tumor and normal lung tissues was examined by immunohistochemistry, and associations for Id1 with clinicopathological characteristics and patient survival were assessed using Cox regression models and Kaplan Meier survival curves.
Results:
NSCLC cells with high Id1 protein expression were observed to be vulnerable to the treatment of paclitaxel and cisplatin. In the nude mice xenograft model, the tumor growth was reduced to a large degree in the Id1-overexpressing group upon treatment with paclitaxel and cisplatin. There were 60 patients with adenocarcinoma (Ade) and 23 patients with squamous cell carcinoma (SqCC). After surgery followed by adjuvant chemotherapy, the Ade patients with high Id1 expression had an increased disease free survival (DFS) and overall survival (OS) compared to the patients with low Id1, whereas there was no difference in DFS or OS for SqCC patients. The pooled trends of DFS and OS were similar to those of the analyses for Ade patients only.
Conclusion:
In summary, our current data suggest that Id1, a generally negative prognostic factor, predicts a favorable prognosis in the cases of surgically treated NSCLC patients receiving the definitive adjuvant chemotherapy.
